Keshu Zhou
14PUBLICATIONS
80CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (14)
Sort by Publication Date:
|Aug 14, 2025
Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.Yan Xie, Ke-Shu Zhou, Lan-Fang Li
|Sep 24, 2024
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.Jennifer R Brown, Barbara Eichhorst, Nicole Lamanna
|Sep 19, 2024
A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma.Jie Jin, Hong Cen, Keshu Zhou
|Jun 07, 2024
Discovery of a Novel and Potent LCK Inhibitor for Leukemia Treatment via Deep Learning and Molecular Docking.Hao Guo, Zhe-Yuan Shen, Yong-Yi Yuan
|Sep 14, 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis.Yuqin Song, Keshu Zhou, Dehui Zou
|Sep 08, 2023
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.Stephen Opat, Alessandra Tedeschi, Bei Hu
Pageof 3